Moderna shares surge as results beat Wall Street estimates and losses narrow sharply

Published on 1 May 2026

Losses came in far less than analysts forecast

Moderna’s MRNA stock jumped in the US after the pharma company reported results that beat Wall Street expectations. The company posted a loss of $2.52 per share, improving from the prior year and well above the analyst estimate of a $3.96 loss. The surprise miss-to-beat shift sparked buying momentum.

Moderna shares rose after quarterly results topped estimates
Loss narrowed to $2.52 per share versus expected $3.96
Investors reacted positively in the US stock market session

#stocks #earnings #wall street #moderna #mrna

Read the full story at The Economic Times

This summarization was done by Beige for a story published on The Economic Times

Moderna shares surge as results beat Wall Street estimates and losses narrow sharply

The full experience is on mobile.